Tweet MS-SPRINT has become abit of of an MS-SNAIL RACE with a One legged snail. Yep snails have a foot but MS_SPRINT took the drug of interest from the MS-SMART trial and gave us all hope to be dashed. MS-SPRINT was done years ago with Ibudilast. This was an asthma related drug approved in Japan….
Month: January 2026
Overcoming cognitive biases in my life with MS
In the past two years, I’ve started listening to a number of podcasts. That this coincides with my becoming more sedentary is purely coincidental. That my first was the Multiple Sclerosis Podcast is less so for obvious reasons, but today I listen to podcasts about more than just multiple sclerosis (MS). I like being entertained,…
New research hints MS may not follow one single disease pattern
Multiple sclerosis (MS) may follow two distinct biological paths that differ in how early and how quickly nerve damage develops, according to a new study. Using artificial intelligence (AI) to analyze brain MRI scans together with a blood test linked to nerve damage, researchers identified one MS pattern marked by earlier, more severe damage and…
Privosegtor granted FDA breakthrough status for optic neuritis
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to privosegtor, an experimental treatment from Oculis that aims to protect the vision of people experiencing acute optic neuritis. This condition, which involves inflammation of the optic nerve, is a common and often debilitating symptom of multiple sclerosis (MS) that can lead to vision…
B cell depleters influnece T cells
Tweet How do B cell depleters work?. Some say because it depletes CD20+, T cells, but affects other T cells as well so it suggests B cells are doing a lot with the immune system. This study looks at ofatumumab and T cell numbers drop with time. The T cell level drops but remains within…
For the new year, I’ll be setting intentions instead of resolutions
For many people, the arrival of a new year is a celebration of the possibilities that lie ahead. For those of us living with multiple sclerosis (MS), it’s often quieter and more internal. It’s often less about making resolutions and more about facing a reckoning. When you live with MS, a new year doesn’t feel…
New biomarker may help identify MS patients for BTK inhibitors
The balance between two immune signaling molecules — CXCL13 and BAFF — may help identify the hard-to-treat inflammation in the brain and spinal cord that’s thought to be a major driver of disability progression in multiple sclerosis (MS), a study found. The findings may help identify which patients are most likely to benefit from BTK…
FDA approves generic injection to help manage MS
The U.S. Food and Drug Administration (FDA) has approved Scinopharm Taiwan’s glatiramer acetate injection, a generic of Copaxone, to treat multiple sclerosis (MS). Scinopharm is the first pharmaceutical company in Taiwan to win U.S. approval for glatiramer acetate, marking a significant milestone for the country in the global industry, according to a company press release….
Generic fingolimod is it inferior?
Tweet Yesterday I did a post on Tysabri and Tyruko and we had a few posts saying the biosimilar was not the same. Some have taken to the media to aire this view, but there have been many other me-toos been introduced to the MS word. So what do you think about this? We have…
Toward a Global Research Plan for Preventing Multiple Sclerosis
The post Toward a Global Research Plan for Preventing Multiple Sclerosis appeared first on MS Australia. Source: www.msaustralia.org.au